Claims for Patent: 6,432,639

Summary for Patent: 6,432,639

Title:	Isolated CYP3A4 nucleic acid molecules and detection methods
Abstract:	Genetic polymorphisms are identified in the human CYP3A4 gene that alter CYP3A4-dependent drug metabolism. Nucleic acids comprising the polymorphic sequences are used to screen patients for altered metabolism for CYP3A4 substrates, potential drug-drug interactions, and adverse/side effects, as well as diseases that result from environmental or occupational exposure to toxins. The nucleic acids are used to establish animal, cell and in vitro models for drug metabolism.
Inventor(s):	Lichter; Jay B. (San Diego, CA), Guida; Marco (San Diego, CA)
Assignee:	DNA Sciences Laboratories, Inc. (Morrisville, NC)
Application Number:	09/144,367
Patent Claims:	1. An isolated nucleic acid molecule, wherein said isolated nucleic acid molecule specifically hybridizes to and detects a CYP3A4 variant gene that differs from the CYP3A4 wild-type gene by having one or more polymorphisms selected from the group consisting of: (a) a substitution of a G nucleotide for an A nucleotide at position -392 of the promoter of said CYP3A4 gene with respect to the start codon of said CYP3A4 gene; (b) an insertion of nucleotides 10-51 of SEQ ID NO:46 at position +506 of intron 3 of said CYP3A4 gene with respect to the first nucleotide of said intron 3; (c) a substitution of a C nucleotide for a G nucleotide at position -9 of intron 4 of said CYP3A4 gene with respect to the first nucleotide of exon 5; (d) a substitution of a G nucleotide for a T nucleotide at position +52 of intron 6 of said CYP3A4 gene with respect to the first nucleotide of said intron 6; (e) a substitution of a T nucleotide for a C nucleotide at position 579 with respect to the first nucleotide of the coding sequence of said CYP3A4 gene; (f) a substitution of a G nucleotide for a T nucleotide at position +34 of intron 7 of said CYP3A4 gene with respect to the first nucleotide of said intron 7; (g) a substitution of an A nucleotide for a G nucleotide at position +12 of intron 10 of said CYP3A4 gene with respect to the first nucleotide of said intron 10; and, (h) a substitution of a T nucleotide for a C nucleotide at position -11 of intron 11 of said CYP3A4 gene with respect to the first nucleotide of exon 12; and wherein said isolated nucleic acid molecule is selected from the group consisting of: (i) an isolated nucleic acid molecule selected from the group consisting of: an isolated nucleic acid molecule consisting essentially of SEQ ID NO:44, an isolated nucleic acid molecule consisting essentially of SEQ ID NO:46, an isolated nucleic acid molecule consisting essentially of 18-19 contiguous nucleotides of SEQ ID NO:48, an isolated nucleic acid molecule consisting essentially of 18-19 contiguous nucleotides of SEQ ID NO:50, an isolated nucleic acid molecule consisting essentially of 15-19 contiguous nucleotides of SEQ ID NO:52, an isolated nucleic acid molecule consisting essentially of 18-19 contiguous nucleotides of SEQ ID NO:54, an isolated nucleic acid molecule consisting essentially of 18-19 contiguous nucleotides of SEQ ID NO:56, and an isolated nucleic acid molecule consisting essentially of 15-18 contiguous nucleotides of SEQ ID NO:58; (ii) a nucleic acid probe consisting essentially of about 100 or fewer nucleotides, wherein said probe comprises said nucleic acid molecule of (i); (iii) a recombinant nucleic acid molecule consisting essentially of said nucleic acid molecule of (i) and a vector sequence; (iv) an isolated CYP3A4 variant gene that differs from a wild-type CYP3A4 gene only by having one or more polymorphisms selected from the group consisting of (a)-(h), wherein said isolated CYP3A4 gene comprises said nucleic acid molecule of (i); (v) an at least 18 nucleotide fragment of the isolated CYP3A4 variant gene of (iv), wherein said fragment comprises said nucleic acid molecule of (i); and, (vi) a nucleic acid molecule that is fully complementary to a nucleic acid molecule of (i), (ii), (iii), (iv) or (v). 2. The isolated nucleic acid molecule of claim 1, wherein said isolated nucleic acid molecule is a probe of 100 or fewer nucleotides, wherein said probe comprises said nucleic acid molecule of (i). 3. The isolated nucleic acid molecule of claim 2, wherein said probe is a probe of 50 or fewer nucleotides. 4. The isolated nucleic acid molecule of claim 2, wherein said probe is conjugated to a detectable marker. 5. An array of oligonucleotides comprising at least one probe of claim 2. 6. The isolated nucleic acid molecule of claim 1, wherein said nucleic acid molecule is the recombinant nucleic acid molecule of (iii). 7. The isolated nucleic acid molecule of claim 1, wherein said nucleic acid molecule is the isolated CYP3A4 variant gene of (iv). 8. The isolated nucleic acid molecule of claim 1, wherein said nucleic acid molecule is the at least 18 nucleotide fragment of (v). 9. The isolated nucleic acid molecule of claim 1, wherein said nucleic acid molecule is selected from the group consisting of SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, and SEQ ID NO:58. 10. A method of detecting a CYP3A4 gene in a nucleic acid sample, said method comprising: (A) obtaining a nucleic acid sample that has been isolated from an individual; (B) contacting said nucleic acid sample with a nucleic acid probe, wherein said nucleic acid probe specifically hybridizes to and detects a CYP3A4 variant gene that differs from the CYP3A4 wild-type gene by having one or more polymorphisms selected from the group consisting of: (a) a substitution of a G nucleotide for an A nucleotide at position -392 of the promoter of said CYP3A4 gene with respect to the start codon of said CYP3A4 gene; (b) an insertion of nucleotides 10-51 of SEQ ID NO:46 at position +506 of intron 3 of said CYP3A4 gene with respect to the first nucleotide of said intron 3; (c) a substitution of a C nucleotide for a G nucleotide at position -9 of intron 4 of said CYP3A4 gene with respect to the first nucleotide of exon 5; (d) a substitution of a G nucleotide for a T nucleotide at position +52 of intron 6 of said CYP3A4 gene with respect to the first nucleotide of said intron 6; (e) a substitution of a T nucleotide for a C nucleotide at position 579 with respect to the first nucleotide of the coding sequence of said CYP3A4 gene; (f) a substitution of a G nucleotide for a T nucleotide at position +34 of intron 7 of said CYP3A4 gene with respect to the first nucleotide of said intron 7; (g) a substitution of an A nucleotide for a G nucleotide at position +12 of intron 10 of said CYP3A4 gene with respect to the first nucleotide of said intron 10; and, (h) a substitution of a T nucleotide for a C nucleotide at position -11 of intron 11 of said CYP3A4 gene with respect to the first nucleotide of exon 12; and wherein said nucleic acid probe is selected from the group consisting of: (i) a nucleic acid probe consisting essentially of a nucleic acid sequence selected from the group consisting of SEQ ID NO:44, SEQ ID NO:46, 18-19 contiguous nucleotides of SEQ ID NO:48, 18-19 contiguous nucleotides of SEQ ID NO:50, 15-19 contiguous nucleotides of SEQ ID NO:52, 18-19 contiguous nucleotides of SEQ ID NO:54, 18-19 contiguous nucleotides of SEQ ID NO:56, and 15-18 contiguous nucleotides of SEQ ID NO:58; (ii) a nucleic acid probe consisting essentially of an at least 18 nucleotide fragment of an isolated CYP3A4 variant gene, wherein said variant gene differs from a wild-type CYP3A4 variant gene only by having one or more polymorphisms selected from the group consisting of (a)-(h), and wherein said fragment comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO:44, SEQ ID NO:46, 18-19 contiguous nucleotides of SEQ ID NO:48, 18-19 contiguous nucleotides of SEQ ID NO:50, 15-19 contiguous nucleotides of SEQ ID NO:52, 18-19 contiguous nucleotides of SEQ ID NO:54, 18-19 contiguous nucleotides of SEQ ID NO:56, and 15-18 contiguous nucleotides of SEQ ID NO:58; and, (iii) a nucleic acid probe that is fully complementary to a nucleic acid sequence of (i) or (ii); and, (C) detecting specific hybridization between said probe and said nucleic acid sample as indicative of the presence of a CYP3A4 gene in said nucleic acid sample. 11. The method of claim 10, wherein said step of contacting comprises contacting said nucleic acid sample with an array of oligonucleotides comprising said nucleic acid probe. 12. The method of claim 10, wherein said nucleic acid sample is a genomic DNA sample. 13. The method of claim 10, wherein said nucleic acid sample is an RNA sample. 14. An isolated nucleic acid molecule which specifically hybridizes to and detects CYP3A4 variant gene that differs from the CYP3A4 wild-type gene by having one or more polymorphisms, wherein said isolated nucleic acid molecule is selected from the group consisting of: (I) a sense strand of a CYP3A4 variant gene, wherein said variant gene differs from a wild-type CYP3A4 gene in that said variant gene has a single polymorphism selected from the group consisting of: (a) a substitution of a G nucleotide for an A nucleotide at position -392 of the promoter of said CYP3A4 gene with respect to the start codon of said CYP3A4 gene; (b) an insertion of nucleotides 10-51 of SEQ ID NO:46 at position +506 of intron 3 of said CYP3A4 gene with respect to the first nucleotide of said intron 3; (c) a substitution of a C nucleotide for a G nucleotide at position -9 of intron 4 of said CYP3A4 gene with respect to the first nucleotide of exon 5; (d) a substitution of a G nucleotide for a T nucleotide at position +52 of intron 6 of said CYP3A4 gene with respect to the first nucleotide of said intron 6; (e) a substitution of a T nucleotide for a C nucleotide at position 579 with respect to the first nucleotide of the coding sequence of said CYP3A4 gene; (f) a substitution of a G nucleotide for a T nucleotide at position +34 of intron 7 of said CYP3A4 gene with respect to the first nucleotide of said intron 7; (g) a substitution of an A nucleotide for a G nucleotide at position +12 of intron 10 of said CYP3A4 gene with respect to the first nucleotide of said intron 10; and, (h) a substitution of a T nucleotide for a C nucleotide at position -11 of intron 11 of said CYP3A4 gene with respect to the first nucleotide of exon 12; (II) an at least 18 nucleotide fragment of the sense strand of (I), wherein said fragment includes the single polymorphism present in the sense strand of (I); and (III) a nucleic acid molecule fully complementary to (I) or (II). 15. The isolated nucleic acid molecule of claim 1, wherein said molecule further comprise an exogenous CYP3A4 promoter operably linked to a reporter gene.

Details for Patent 6,432,639

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2017-09-10
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2017-09-10
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2017-09-10